Financials Harvard Apparatus Regenerative Technology Inc.
Equities
HRGN
US09074M2026
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.25 USD | -8.54% | -7.79% | -54.91% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 11.68 | 15.77 | 11.74 | 24.75 | 66.96 | 69.6 |
Enterprise Value (EV) 1 | 10.37 | 15.04 | 11.3 | 23.45 | 65.85 | 69.21 |
P/E ratio | -1.22 x | -1.66 x | -2.26 x | -2.9 x | -9.98 x | -7.44 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | 675,700,447 x |
EV / Revenue | - | - | - | - | - | 671,972,291 x |
EV / EBITDA | -1.41 x | -1.74 x | -2.2 x | -2.75 x | -10.9 x | -7.73 x |
EV / FCF | -2.06 x | -4.55 x | -4.5 x | 40.3 x | -10.3 x | -28.8 x |
FCF Yield | -48.4% | -22% | -22.2% | 2.48% | -9.7% | -3.48% |
Price to Book | 5.93 x | 15.1 x | 10.4 x | -8.17 x | -21 x | 42.3 x |
Nbr of stocks (in thousands) | 5,670 | 7,843 | 9,388 | 10,761 | 12,174 | 13,947 |
Reference price 2 | 2.060 | 2.010 | 1.250 | 2.300 | 5.500 | 4.990 |
Announcement Date | 19-03-29 | 20-03-27 | 21-04-13 | 22-03-31 | 23-03-30 | 24-03-28 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | 0.103 |
EBITDA 1 | -7.38 | -8.656 | -5.141 | -8.529 | -6.014 | -8.955 |
EBIT 1 | -7.641 | -8.87 | -5.325 | -8.636 | -6.066 | -8.99 |
Operating Margin | - | - | - | - | - | -8,728.16% |
Earnings before Tax (EBT) 1 | -7.529 | -8.332 | -4.865 | -7.978 | -6.073 | -8.945 |
Net income 1 | -7.529 | -8.332 | -4.865 | -7.978 | -6.073 | -8.945 |
Net margin | - | - | - | - | - | -8,684.47% |
EPS 2 | -1.687 | -1.208 | -0.5532 | -0.7928 | -0.5509 | -0.6705 |
Free Cash Flow 1 | -5.025 | -3.303 | -2.511 | 0.5815 | -6.388 | -2.406 |
FCF margin | - | - | - | - | - | -2,335.44% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 19-03-29 | 20-03-27 | 21-04-13 | 22-03-31 | 23-03-30 | 24-03-28 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 1.31 | 0.72 | 0.44 | 1.3 | 1.11 | 0.38 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -5.02 | -3.3 | -2.51 | 0.58 | -6.39 | -2.41 |
ROE (net income / shareholders' equity) | -279% | -545% | -439% | 838% | 595% | -679% |
ROA (Net income/ Total Assets) | -124% | -240% | -164% | -274% | -178% | -224% |
Assets 1 | 6.052 | 3.476 | 2.973 | 2.913 | 3.417 | 3.991 |
Book Value Per Share 2 | 0.3500 | 0.1300 | 0.1200 | -0.2800 | -0.2600 | 0.1200 |
Cash Flow per Share 2 | 0.2300 | 0.1100 | 0.1100 | 0.1200 | 0.1000 | 0.0300 |
Capex 1 | 0.13 | 0.13 | 0.01 | - | 0.01 | 0.01 |
Capex / Sales | - | - | - | - | - | 10.68% |
Announcement Date | 19-03-29 | 20-03-27 | 21-04-13 | 22-03-31 | 23-03-30 | 24-03-28 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-54.91% | 32.21M | |
+8.88% | 221B | |
+8.68% | 186B | |
+14.25% | 137B | |
+28.18% | 109B | |
+14.65% | 52.68B | |
+4.48% | 50.86B | |
+4.39% | 42.53B | |
+7.00% | 37.76B | |
+26.06% | 31.86B |
- Stock Market
- Equities
- HRGN Stock
- Financials Harvard Apparatus Regenerative Technology Inc.